Endogenous Mechanisms of Inactivation of the Endothelium Tumor

Breast Cancer Clinical Trial

— BreastIls  

Official title:

Endogenous Mechanisms of Inactivation of the Endothelium Tumor

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03667612
• Other study ID #: BreastIls-1605
• Status: Active, not recruiting
• Start date: January 31, 2018
• Est. completion date: October 2019

Study information

• Verified date: August 2018
• Source: Centre Oscar Lambret
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The role of immunity in the development of cancers, and the associated escape mechanisms, have attracted renewed interest since the publication of tests testing immunological checkpoint inhibitors. One of the steps in the probably least studied immunological response is the penetration of immunocompetent cells within the tumor across the vascular barrier. This infiltration is suggested as a prognostic and predictive marker of treatment response, particularly in triple negative HER2 (Human Epidermal Growth Factor Receptor-2) overexpressing breast cancers. The methods of evaluating these infiltrates are complex and have been the subject of recommendations.

A better understanding of the mechanisms of infiltration of immunity cells within tumors will certainly help to better understand the impact of cancer treatments and develop new therapeutic strategies.

It is this issue of vascular endothelium that Dr. Soncin's team is developing as part of an INCa (Institut National du cancer) project. The egfl7 / VE-statin (vascular endothelial-statin) gene is thought to be involved in transendothelial passage of immune cells from vascular lumen to tumor. Its expression has already been studied in a series of breast cancers. Other markers of endothelial activation are currently being identified.

The main objective of this project will be to better understand the behavior of the endothelium in a population of breast cancer where the infiltrate in immune cells is precisely likely to play a leading role. This retrospective cohort of 250 to 300 cases treated with adjuvant and neoadjuvant will be immunologically characterized using the recommendations of Salgado et al. that a multicentric team of pathologists will take ownership. This evaluation will be counter-appraised.

Once our cohort is immunologically characterized, our project will focus on better understanding the endothelial mechanisms involved: which cells? immunophenotyping of immunity cells. By which vessels? (measurement of densities in blood and lymphatic vessels, density in HEV). By what mechanisms? Do the actors identified in vitro within the Inca project have an in vivo translation

Description:

The main objective of this project will be to better understand the behavior of the endothelium in a population of breast cancer where the infiltrate in immune cells is precisely likely to play a leading role. This retrospective cohort of 250 to 300 cases treated with adjuvant and neoadjuvant will be immunologically characterized using the recommendations of Salgado et al., that a multicentric team of pathologists will take ownership. This evaluation will be counter-appraised.

Once our cohort is immunologically characterized, our project will focus on better understanding the endothelial mechanisms involved: which cells? immunophenotyping of immunity cells. By which vessels? (measurement of densities in blood and lymphatic vessels, density in HEV). By what mechanisms? Do the actors identified in vitro within the Inca project have an in vivo translation

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 70
• Est. completion date: October 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women aged 18 and over

• Confirmed histological diagnosis of breast carcinoma at localized or metastatic stage or colorectal cancer

• Treated at the Oscar Lambret Center or the Henri Becquerel Center between 1/1/2005 and 31/12/2007

• Having undergone surgery for excision of the primary tumor and / or a metastasis

• resected specimen available

• Patients who gave their consent

Exclusion Criteria:

• History of other cancers

• Breast or colic tumors with other histological profiles

• Patient treated for breast or colonic recurrence

Related Conditions & MeSH terms

• Breast Cancer
• Colon Cancer

Locations

Country	Name	City	State
France	Centre Oscar Lambret	Lille
France	Centre Henri Becquerel	Rouen

Sponsors (2)

Lead Sponsor	Collaborator
Centre Oscar Lambret	Institut de Biologie de Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	correlation between the expression levels of the genes involved in the regulation of endothelial activation and the degree of tumor-infiltrating lymphocytes	The expression of the genes (egfl7, SetD5, other genes and microRNAs) will be evaluated quantitatively by RT-PCR. The amount of RNA obtained corresponds to a relative amount of RNA relative to the amount of RNA measured in a sample used as a reference.; A semi-quantitative evaluation will also be carried out by in situ hybridization techniques and immunohistochemistry of endothelial expression of endothelial activation regulation markers: 0+ no labeled vessels, 1+ <30% of labeled vessels, 2+ between 30 and 60% of marked vessels, 3+> 60% of marked vessels The lymphocyte infiltration will be evaluated by measuring the ratio between the surface infiltrated by mononuclear cells and the tumor surface (for intratumoral TILS) or stromal (for total stromal TILS). The analysis will be done on H & E slides and the data will be expressed as a percentage.	24 months
Secondary	reproducibility of lymphocyte infiltration assessment on H & E slides		24 months
Secondary	study of the subgroups of the cohort with a predominant lymphocytes infiltration cancer	description of subpopulations of immunocompetent cells by specific complementary immunolabeling of CD4 + T lymphocytes (mature T helper lymphocytes expressing the surface protein CD4), cytotoxic CD8 (T lymphocytes expressing the surface protein CD8), T-regulatory (CD25 / FoxP3), B-cell lymphocytes , macrophages and NK (Natural Killer) cells	24 months
Secondary	Cell density description	Description of density in vascular endothelial (CD31 / 34 labeled), lymphatic (LYVE / podoplanin-labeled) and HEV (High endothelial venom MECA79 + (Rat Monoclonal Anti-Peripheral Node Addressin Antibody )) cells and correlation with lymphocyte infiltrate levels	24 months
Secondary	Prognostic value assessment	Evaluate the prognostic value of biomarkers and lymphocytic infiltrate in terms of Global Survival and Survival Without Recurrence	24 months
Secondary	Expression levels of genes involved in the regulation of endothelial activation	In subpopulations of patients treated in neo-adjuvant or metastatic situations: assess the expression levels of genes involved in the regulation of endothelial activation	24 months
Secondary	treatment response data	In subpopulations of patients treated in neo-adjuvant or metastatic situations: assess the treatment response data (chemotherapy in patients with breast cancer, chemotherapy and antiangiogenic in colon cancers)	24 months
Secondary	lymphocytic infiltrate data	For patients treated for breast cancer: study lymphocytic infiltrate data	24 months
Secondary	the existence of a BRCA1 and or BRCA 2 mutation (which are tumour suppressor genes)	For patients treated for breast cancer: assess the existence of a BRCA1 and or BRCA 2 mutation	24 months
Secondary	association between lymphocytic infiltrate data and the RER phenotype (the replication error phenotype)	For patients treated for colon cancer: to study the association between lymphocytic infiltrate data and the RER phenotype	24 months
Secondary	The RER phenotype (the replication error phenotype)	For patients treated for colon cancer: to study the RER phenotype	24 months